WHO's delirium work covers medication safety and deprescribing for older adults, and people with mild cognitive impairment sit on both sides of the evidence. Some drug studies excluded them, while one long-term-care study enrolled them directly.
Delirium means sudden, fluctuating confusion that disrupts attention and awareness. Mild cognitive impairment means greater memory or thinking problems than expected for age but less severe than dementia, reports Alzheimers.gov in the federal MCI overview. That distinction shapes drug risk and drug choices.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is WHO building in 2026?
- Why do medicines matter more with MCI?
- Who was left out of drug trials?
- Who with MCI was studied directly?
- What to ask at a medication review?
What is WHO building in 2026?
The World Health Organization is developing its first global guideline on prevention, diagnosis and management of delirium in older adults, stated in the WHO guideline notice. The scope explicitly includes medication safety and deprescribing. That makes drugs a central prevention question, not a side issue. The World Health Organization describes delirium as common, serious and often preventable in older adults.
It links delirium to higher illness, death, functional decline and health-care costs, yet says it remains under-recognized. For readers, the message is direct: prevention deserves the same attention as treatment. The 2026 work is still in a preparatory evidence-review stage. The World Health Organization sought a methodologist to facilitate Guideline Development Group Session 0, with applications due 7 Oct 2026. Final recommendations are not published yet.
Why do medicines matter more with MCI?
Current prescribing guidance most strongly links anticholinergic drugs, meperidine and benzodiazepines to increased postoperative delirium. The American Geriatrics Society guideline names diphenhydramine and midazolam among the drugs to avoid in older adults, detailed in the postoperative delirium guideline. These are common sleep, allergy, anxiety and procedure drugs.
MCI raises the stakes because thinking reserve is already reduced. The condition carries higher risk of progressing to Alzheimer's or related dementia. A June 2026 postoperative study, reported via Mass General Brigham, found delirium predicted faster long-term cognitive decline than typical MCI, and rehospitalization did not explain the effect.
Who was left out of drug trials?
Many perioperative delirium medication trials did not study people with prior cognitive impairment. That gap matters for deprescribing because the highest-risk patients were missing from the test group. Results may not transfer cleanly to someone with MCI.
A 2026 remimazolam-versus-propofol trial shows the limit clearly, described in the anesthesia trial report. The Frontiers in Medicine authors excluded preoperative delirium or dementia. They stated results apply only without preexisting cognitive dysfunction.
Who with MCI was studied directly?
People with MCI were specifically studied for delirium risk in the MDD cohort listed as ClinicalTrials.gov NCT05113446. It enrolls adults 65 and older in long-term care with doctor-diagnosed MCI. Entry requires MMSE scores of 18 to 23.
The study tracks delirium over 30 days using S-CAM, a short confusion assessment method. That design captures new delirium in a known MCI group. It offers the kind of MCI-specific evidence that anesthesia trials often lack.
What to ask at a medication review?
Use the gap to guide questions, not fear. Bring every prescription, over-the-counter product, sleep aid and allergy pill. Ask whether each drug is still needed, whether a lower dose works, and what the stop plan is.
- List all sedating drugs, especially nighttime sleep and allergy products
- Ask about anticholinergic load and benzodiazepine alternatives
- Review pain medicines, including meperidine history and current options
- For surgery, ask how MCI changes anesthesia and delirium monitoring
- Set one follow-up date to review changes and withdrawal symptoms
You Might Also Like
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Who Was Studied and Who Was Not for People With Mild Cognitive Impairment
- The Long-Term Care Data Cooperative and Dementia Research in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- NHATS and NSOC Dementia Care Data Priorities in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
